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Abstract
Background: Severe Combined Immune Deficient (SCID)/Urokinase-type Plasminogen Activator (uPA) mice undergo liver
failure and are useful hosts for the propagation of transplanted human hepatocytes (HH) which must compete with
recipient-derived hepatocytes for replacement of the diseased liver parenchyma. While partial replacement by HH has
proven useful for studies with Hepatitis C virus, complete replacement of SCID/uPA mouse liver by HH has never been
achieved and limits the broader application of these mice for other areas of biomedical research. The herpes simplex virus
type-1 thymidine kinase (HSVtk)/ganciclovir (GCV) system is a powerful tool for cell-specific ablation in transgenic animals.
The aim of this study was to selectively eliminate murine-derived parenchymal liver cells from humanized SCID/uPA mouse
liver in order to achieve mice with completely humanized liver parenchyma. Thus, we reproduced the HSVtk (vTK)/GCV
system of hepatic failure in SCID/uPA mice.
Methodology/Principal Findings: In vitro experiments demonstrated efficient killing of vTK expressing hepatoma cells after
GCV treatment. For in vivo experiments, expression of vTK was targeted to the livers of FVB/N and SCID/uPA mice. Hepatic
sensitivity to GCV was first established in FVB/N mice since these mice do not undergo liver failure inherent to SCID/uPA
mice. Hepatic vTK expression was found to be an integral component of GCV-induced pathologic and biochemical
alterations and caused death due to liver dysfunction in vTK transgenic FVB/N and non-transplanted SCID/uPA mice. In
SCID/uPA mice with humanized liver, vTK/GCV caused death despite extensive replacement of the mouse liver parenchyma
with HH (ranging from 32–87%). Surprisingly, vTK/GCV-dependent apoptosis and mitochondrial aberrations were also
localized to bystander vTK-negative HH.
Conclusions/Significance: Extensive replacement of mouse liver parenchyma by HH does not provide a secure therapeutic
advantage against vTK/GCV-induced cytotoxicity targeted to residual mouse hepatocytes. Functional support by engrafted
HH may be secured by strategies aimed at limiting this bystander effect.
Citation: Douglas DN, Kawahara T, Sis B, Bond D, Fischer KP, et al. (2010) Therapeutic Efficacy of Human Hepatocyte Transplantation in a SCID/uPA Mouse Model
with Inducible Liver Disease. PLoS ONE 5(2): e9209. doi:10.1371/journal.pone.0009209
Editor: Brett Lindenbach, Yale University, United States of America
Received July 22, 2009; Accepted January 24, 2010; Published February 18, 2010
Copyright:  2010 Douglas et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits
unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Funding: This work was supported by Canadian Institutes of Health Research Grant # G019000018 and Alberta Heritage Foundation for Medical Research. The
funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.
Competing Interests: Dr. Kneteman is the Chief Executive Officer and owns stock in KMT Hepatech, Inc. Dr. Lorne Tyrrell owns stock in KMT Hepatech, Inc.
* E-mail: donnad@ualberta.ca
Introduction
The human liver is a crucial organ for pharmacological studies
aimed at developing new human medicines. In the preclinical
stage, the pharmacokinetics of a drug candidate is investigated
using human-derived sources or experimental animals. Because of
species differences, human liver microsomes and human hepato-
cytes (HH) in primary culture are recognized as better tools and
are frequently used during drug development. Human liver
microsomes can be stored for a few years without the loss of
enzyme activities[1,2,3] but cannot be used to evaluate the
induction potencies of a drug. Induction is often clinically
significant and represents the net increase in the levels of one or
more drug metabolizing enzymes, as a result of increased de novo
protein synthesis or protein stabilization[4,5]. Human hepatocytes
express all the drug metabolizing enzymes, but enzyme activities
are often reduced by cell culture methods[6,7]. An artificial
human liver is one of the best approaches for predicting human
pharmacokinetics and safety in the preclinical stage.
We have developed the SCID/uPA mouse model of human
liver, based on transgenic mice in which uPA expression is
targeted to hepatocytes (Alb-uPA), and this achievement has
advanced our understanding of the in vivo replication properties of
Hepatitis C virus[8]. Alb-uPA mice develop hepatocellular
disease[9] and likewise, the liver from young SCID/uPA mouse
liver initially appears pale. Red foci become visible at approxi-
mately 2 weeks old and gradually expand until the pale liver (PL) is
replaced by confluent red, regenerative nodules (RN); a process
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uPA transgene[9,10]. RN have been shown to arise from the
proliferation of individual mouse hepatocytes (MH) that have
deleted theuPAtransgene[9];aneventthat ismore likelytooccurin
heterozygous uPA transgenic mice since individual hepatocyts have
only one copy of the transgene. However, despite early transplan-
tation[8], HH transplanted into SCID/uPA mice (homozygous for
the uPA transgene) will compete with uPA-deficient MH for
replacement of the mouse liver parenchyma.As such, variable levels
of human chimerism is often achieved[8,10,11] and complete
humanization of mouse liver has never been achieved. SCID/uPA
mice with high levels of human liver chimerism have been shown to
retain normal pharmacological responses and therefore are
potentially useful for human drug metabolism studies[11]. Given
the marked differences in drug metabolism between humans and
mice[12], there is a need for complete humanization of SCID/uPA
mouse liver.
It is well known that differentiated hepatocytes of adult liver will
transiently enter the cell cycle and proliferate to restore lost liver
mass after parenchymal damage or resection[13,14,15,16]; a
phenomenon that is especially evident following 70% partial
hepatectomy (PH)[17]. In Alb-uPA mice, RN have been shown to
preferentially respond further to the strong mitotic stimulus of
hepatectomy relative to PL[9]. We hypothesized that conditional
ablation of residual MH in chimeric liver of SCID/uPA mice
would leave only HH capable of this mitotic response and their
selective proliferation would promote complete humanization of
mouse liver.
The Herpes Simplex Virus type 1 thymidine kinase (vTK)
coding region is a component of a strategy for cell-type specific
ablation in transgenic animals in response to the pro-drug
ganciclovir (GCV) (reviewed in[18]). We reproduced vTK/
GCV-induced hepatic failure of mouse liver[19,20] in SCID/
uPA mice for the conditional ablation of residual MH with the
intention of producing mice with consistently greater levels of
human liver chimerism.
Results
Immunohistology of Chimeric Mouse Liver
Histopathological analysis of chimeric liver from a 12 week old
SCID/uPA mouse (transplanted at 5 days old),demonstrated two
types of lobules comprised of HH or MH (Fig. 1, i) which are
separated by murine (M) thin connective tissue and portal tracts
(short arrow), where ceroid-laden macrophages cluster (iii,
arrowheads). HH are larger than MH and have a pale cytoplasm
corresponding to glycogen storage (ii positive by periodic acid
Schiff (PAS), and iii negative by diastase PAS,).
vTK/GCV Cytotoxicity in Huh7 Cells
Immunoblot analysis demonstrated Huh7 cellular clones (1 and
6) stably transfected with pCI-vTK expressed vTK protein
(Fig. 2A). These vTK expressing cellular clones started to detach
48 h post exposure to a single dose (50 mmolL
21) GCV whereas
the mock transfected cells grew and proliferated normally.
Increased cell death was also assessed by MTT assay (Fig. 2B).
Stable expression of vTK in Huh7 cells significantly reduced their
survival rate in the presence of the toxic pro-drug GCV.
vTK/GCV Induced Liver Failure in FVB/N Mice
Female vTK+FVB/N mice (derived from a single female
founder) were crossed with wild-type FVB/N males and the vTK
status of offspring was determined by vTK PCR-based genotyping
of tail biopsies in order to identify vTK+ and vTK-FVB/N mice
from which an experimental cohort to test vTK/GCV-inducible
hepatic injury was selected (Table 1). Experimental mice had to be
sacrificed after 5 days of dosing due to GCV-induced health crisis
seen only with vTK+ mice. Baseline serum aminotransferases
Figure 1. Histology of chimeric SCID/uPA liver at 12 weeks old. Engrafted human hepatocytes (HH, brown nuclei) in paraffin embedded liver
sections were distinguished from mouse hepatocytes (MH, blue nuclei) and other murine constituents (M, blue nuclei) by hybridization with
fluoresceinated Alu probe (i, left). Serial sections were analyzed by PAS staining (right) without (ii) or with (iii) prior diastase treatment. Ceroid
macrophages (iii, arrowheads). (Original magnification 650).
doi:10.1371/journal.pone.0009209.g001
SCID/uPA Mouse Liver Suicide
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respectively and were found to be substantially increased (to .200
and .800 IU/mL, for ALT and AST, respectively) in vTK+ mice
that received 25 and 50 mg/kg GCV and in whom GCV dosing
had the most severe impact (Table 1). Creatinine concentrations
remained within normal ranges (30–58 mmol/L) indicating
normal kidney function. The appearance of livers from vTK+
FVB/N mice ranged from very red (as seen with mice that
remained healthy, +++) to very pale (as seen with the most
severlely impacted, +). The health and gross appearance of livers
from vTK-FVB/N mice remained normal at all GCV doses.
Tissue Distribution of vTK in vTK+FVB/N Mice
Various tissues from vTK+FVB/N mice underwent immuno-
blot and RT-PCR analysis for vTK expression (Fig. 3). Full-length
vTK protein (47 kDa) was detected exclusively in the livers of
vTK+ mice and was absent from vTK- mice (Fig. 3A, left). A
smaller immunoreactive protein was detected in the testis of vTK+
mice (Fig. 3A, right) but was absent from testis from vTK- mice
(not shown). RT-PCR for vTK (Fig. 3B, left) and delta-vTK
(Fig. 3B, right) confirmed the presence of full length vTK mRNA
in the liver and delta-vTK mRNA in the testis from vTK+ mice (as
shown for mouse vTK+ mouse 3.3). The detection of a similar
amplicon in heart was found to be due to genomic DNA
contamination of the total RNA prepared from heart tissue since
this amplicon disappeared when the total RNA was treated with
DNase (not shown). An amplicon corresponding to delta-vTK was
also detected in the liver of vTK+ mice and was expected since the
primers for delta-vTK RT-PCR are expected to amplify cDNA
generated from full length vTK transcripts (refer to Materials and
Methods section). Transcripts for delta-vTK were absent in the
testis and liver from vTK- mice (B, right for vTK- mouse 3.2).
vTK/GCV Pathological Changes in FVB/N Mouse Liver
vTK+ FVB/N livers with no GCV treatment showed normal
histology (Fig. 4A). However, GCV-treated vTK+FVB/N mouse
livers showed diffuse cytoplasmic and nuclear enlargement in
hepatocytes with patchy areas of confluent necrosis and abundant
acidophilic bodies and apoptotic bodies (Fig. 4B–C). In addition, a
prominent mononuclear inflammatory cell infiltration in lobular
and portal areas was observed. TUNEL stain showed increased
apoptotic nuclei in livers from mice that received 25 and 50 mg/
Figure 2. Functional expression of vTK in Huh7 cells. A. Huh7
cells were transfected with pCI-vTK and G418-resistant Huh cellular
clones (cl) (1–6) were evaluated for vTK expression (,43 KDa,
arrowheads) by immunoblot analysis. Lmw, low molecular weight
markers; 293TvTK, 293T cells transiently transfected with pCI-vTK. B. In
vitro cytotoxicity of GCV in vTK expressing cells. HuhvTKcl1 and
HuhvTKcl6 cells were incubated with various concentrations of GCV for
72 hours, followed by cell survival quantitation by MTT assay. Data
represent the Mean +/2 S.D from quadruplicate cell cultures for each
GCV dose. Mock, Huh cells that underwent stable selection after
transfection with empty pCIneo vector.
doi:10.1371/journal.pone.0009209.g002
Table 1. vTK/GCV induced liver failure in FVB/N mice.
Animal ID Gender (M/F) vTK Status GCV Dose (mg/kg) Health Status Liver Color ALT (IU/L) T0 Tf AST (IU/L) T0 Tf
3.2 M 2 0 +++ Red 53 49 88 94
3.18 M 2 10 +++ Red 55 51 75 84
3.19 M 2 10 +++ Red 54 52 99 79
3.12 F 2 25 +++ Red 48 44 100 88
3.14 F 2 25 +++ Red 45 49 102 101
3.1 F 2 50 +++ Red 51 48 79 87
3.3 M + 0 +++ Red 48 52 81 101
3.21 M + 10 ++ Pale Red 51 53 91 83
3.11 F + 25 + Pale 53 230 88 896
3.13 M + 25 + Pale 49 247 106 1036
3.9 M + 50 + Very Pale 48 304 73 1211
3.10 F + 50 + Very Pale 51 309 89 1214
GCV was administered to vTK+ and vTK-FVB/N mice for 5 days. Health status ranged from excellent (+++), to poor (++), to critical. ALT and AST levels were determined
for blood draws obtained at 1 hour prior to (T0) and at the end of (Tf) the dosing period. Livers ranged from healthy/normal (red), to very pale at the end of the study.
doi:10.1371/journal.pone.0009209.t001
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(Table 1, +) in comparison to vTK+FVB/N with no GCV trea-
tment (not shown) (10% versus 0% positive nuclei, respectively).
Impact of vTK/GCV in SCID/uPA Mice
Initially, GCV (0, 25, 50 and 100 mg/kg) was administered to
non-transplanted vTK+ and vTK2 SCID/uPA mice. Dosing was
terminated after 10 days due to health crisis seen with vTK+ mice
that received 50 and 100 mg/kg GCV doses; only these mice had
substantially elevated serum aminotransferases. For vTK2 mice
(n=4), the baseline serum ALT and AST levels were 96 +/2
12 IU/L and 293 +/2 23 IU/L, respectively. After the dosing
period, only vTK+ mice that received 50 and 100 mg/kg GCV
doses had substantially elevated ALT/AST levels increasing to
205/801 IU/L and 238/1003 IU/L, respectively. Creatinine
levels remained in the normal range for all mice (not shown).
Like (vTK2)SCID/uPA mouse liver, the majority of the liver
parenchyma in vTK+SCID/uPA mice was occupied by intensely
red colored RN surrounded by pale liver parenchyma (Fig. 5,
upper panels). RN appeared to be particularly sensitive to GCV
since their redness could be diminished by GCV treatment;
the livers of vTK+ mice that received the highest dose of
GCV were universally pale and the discrimination between RN
and surrounding pale liver parenchyma was less evident. Like their
FVB/N counterparts, the livers from vTK+ SCID/uPA mice that
received GCV treatment displayed hepatocytes with dffuse
cytoplasmic and nuclear enlargemenet with mononuclear inflam-
matory cell infiltration (Fig. 5, lower panels). Areas of necrosis,
acidophilic bodies, necrosis and apoptotic bodies were also
featured in these livers but were absent from vTK2 SCID/uPA
mice and vTK+ SCID/uPA mice that did not receive GCV (not
shown). Having confirmed GCV sensitivity in non-transplanted
mice, GCV was administered to transplanted vTK+ and vTK-
SCID/uPA mice that had established levels of human chimerism
(summarized in Table 2). The average pre-dose ALT/AST values
for all vTK2 and vTK+ chimeric mice were within the range of
the non-transplanted vTK-SCID/uPA mice. These were 135 +/2
40 IU/L and 313 +/2 72 IU/L, respectively. The experiment
had to be terminated after 14 days of GCV administration due to
health crisis seen only in vTK+ chimeric mice (with the exception
of mouse v241 which had to be euthanized after 10 days of GCV
administration). These mice had significantly elevated amino-
transferases relative to experimental vTK2 chimeric mice (Fig. 6).
Serum creatinine concentrations remained in the normal range for
all chimeric experimental mice (not shown).
Serum hAAT levels for the majority of transplanted animals (13
of 16 mice) were higher at the end of the GCV treatment period
relative to baseline (Fig. 7A). There was a good correlation be-
tween hAAT levels and replacement index (RI) for histologically
integrated HH (Fig. 7B) and this did not appear to be impacted by
health status since correlations were similar between chimeric mice
that remained healthy and thrived during the course of GCV
dosing (left) and those that were severely impacted and required
euthanasia (right). These results suggest continued expansion of
HH in chimeric mice during the course of GCV administration
but do not exclude the involvement of GCV in a more subtle effect
on engrafted HH. Therefore, increased serum levels of hAAT,
ALT, and AST may reflect bystander killing of vTK-negative HH.
Figure 3. Tissue distribution of vTK in transgenic mice. A. Expression of vTK protein (47 kDa) in various tissues from experimental FVB/N mice
(listed in Table 1) were examined by immunoblot analysis (as shown for vTK+ mice 3.3, 3.21 and 3.11 and vTK2 mice 3.18, 3.12, and 3.12, left panel). A
smaller vTK immunoreactive protein (,39 kDa) was identified in the testis of vTK+ mice. (right panel). B. Expression of vTK mRNA was evaluated in
several tissues obtained from vTK+ mice (as shown for 3.3, left). Expression of delta-vTK mRNA was evaluated in the liver and testis of vTK+ (as shown
fo 3.3, right) and vTK2 (as shown fo 3.2, right) mice.
doi:10.1371/journal.pone.0009209.g003
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and Ultrastructural Architecture of Chimeric Liver
Chimeric livers from vTK+ mice that did not receive GCV
(Fig. 8A) had similar gross appearance and architecture as
chimeric livers sampled from vTK2 mice that received 100
mg/kg GCV (Fig. 8D–F,). These livers are characterized by
multiple red colored foci. Occasionally larger red regenerative
nodules (RN) typically seen in livers of age-matched non-
transplanted mice (as shown in Fig. 5) were also seen (Fig. 8F).
The combination of vTK/GCV resulted in chimeric livers with
am o r ep a l ea p p e a r a n c ew i t has u b s t a n t i a lr e d u c t i o ni nt h e
numbers of red foci that could be discriminated from the pale
liver parenchymal background (Fig. 8B and C for vTK+ chimeric
mice given 25 and 100 mg/kg GCV doses, respectively). Even
large 3-dimentional RN appeared remarkably pale (Fig. 8C)
when compared with the typically red RN seen in chimeric
SCID/uPA mice (as seen with chimeric vTK2 SCID/uPA liver,
Fig. 8F).
Figure 5. Impact of vTK/GCV on non transplanted SCID/uPA mouse liver. Gross Appearance (upper panels) and H&E staining (lower panels)
of livers from non-transplanted and age-matched vTK+SCID/uPA mice (3 months old) treated with 0, 25, 50 and 100 mg/kg GCV (i.p. every 48 h for 10
days). RN, regenerative nodules; PL, pale liver.
doi:10.1371/journal.pone.0009209.g005
Figure 4. GCV induced histopathological changes. A. vTK+FVB/N mice that did not receive GCV showed normal liver histology. B–C. vTK+FVB/
N mice that received 50 mg/kg GCV showed increased cytoplasmic and nuclear enlargement with increased acidophilic bodies (B, arrowhead),
apoptotic bodies (B, arrow), and areas of confluent necrosis (C, arrows) (A–C:Hematoxylin and eosin, original magnification 6200). D. TUNEL
immunostaining showing increased apoptotic nuclei (arrows) in livers post GCV (Immunoperoxidase, original magnification 6200).
doi:10.1371/journal.pone.0009209.g004
SCID/uPA Mouse Liver Suicide
PLoS ONE | www.plosone.org 5 February 2010 | Volume 5 | Issue 2 | e9209Diffuse cytoplasmic and nuclear enlargement were readily
detected in the MH populations of chimeric livers from vTK+
SCID/uPA mice that received GCV but had normal histology in
chimeric livers from vTK2 SCID/uPA (despite 100 mg/kg GCV
dosing, Fig. 9). Increased apoptotic and acidophilic bodies were
detected in both MH and HH populations of chimeric livers from
vTK+ SCID/uPA that received GCV compared to those from
mice that did not receive GCV and vTK2 SCID/uPA mice (not
shown). Serial Alu and TUNEL staining revealed TUNEL-
positive apoptotic nuclei in both MH and HH populations of
chimeric liver from vTK+ mice that received GCV (Fig. 10). By
contrast, TUNEL-positive cells were rarely seen in chimeric livers
from vTK+ SCID/uPA mice that did not receive GCV and
vTK2 chimeric mice (15% versus 1%, respectively, not shown).
Ultrastructural analysis was performed by TEM (Fig. 11). GCV
induced swollen electron lucent mitochondria with aberrant cristae
Table 2. vTK/GCV induced liver failure in chimeric SCID/uPA mice.
Animal ID Gender (M/F) vTK Status GCV Dose (mg/kg) Baseline hAAT (mg/ml) Health Status
Pre-treatment
Body Weight (g)
Post-treatment
Body Weight (g)
V241 M + 100 129 + 15.3 ND
V243 M + 100 684 + 12.25 8.65
V233 M + 100 13 + 15.85 11.20
V232 M + 25 130 + 15.70 10.40
V236 M + 25 207 + 18.10 12.75
V250 F + 25 37 + 10.15 7.70
V237 M + 25 72 + 10.50 10.90
V234 F + 02 7 0 +++ 14.50 13.50
V239 F + 01 4 +++ 16.65 16.85
V240 F + 03 5 +++ 13.30 12.85
V251 F + 02 8 1 +++ 8.90 9.35
V252 F + 01 9 +++ 10.85 11.30
V235 F 2 100 53 +++ 14.70 13.45
V238 F 2 100 317 +++ 14.80 13.85
V244 F 2 100 133 +++ 11.70 9.45
V245 F 2 100 117 +++ 11.60 9.15
GCV dosing in chimeric SCID/uPA/vTK and vTK2 littermates. The degree of human chimerism was determined by serum ELISA for hAAT of blood drawn at 8 weeks
post-transplant (baseline), just 1 hour prior to administration of 0, 25 and 100 mg/kg GCV (i.p.) every 48 hours for up to 14 days at which time the experiment had to be
terminated, and all animals sacrificed, due to morbidity of vTK expressing mice that received 25 and 100 mg/kg GCV (with the exception of V241, which hadt ob e
euthanized after 10 days of GCV dosing). Health status at the end of the treatment period ranged from excellent (+++), to poor (++), to critical and requiring euthenasia
(+) as displayed by weight loss (.10% of pretreatment body mass), decreased activity and lethargy, ruffled fur, and hunched posture. ND: not determined.
doi:10.1371/journal.pone.0009209.t002
Figure 6. Impact of vTK/GCV on serum aminotranserases levels in chimeric SCID/uPA mice. ALT (left) and AST (right) concentrations in
blood sampled from experimental mice (Table 2) 1 h prior to (baseline, white bars) and at the end (endpoint, black bars) of the GCV treatment period
(after 14 days of GCV administration with the exception of V241 whose endpoint sampling was after 10 days of GCV administration at which time
V241 exhibited health crisis and had to be euthanized). Data represent Mean +/2 S.E.M. P,.05 was considered to be significantly different endpoint
levels relative to baseline (**).
doi:10.1371/journal.pone.0009209.g006
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changes (Figure 11A). In contrast, livers from vTK+ SCID/uPA
mice with no GCV (Fig. 11C,D) or vTK2 SCID/uPA mice
(Fig. 11E,F) had normal ultrastructural morphology with unre-
markable mitochondrial matrix and cristae. Ultrastructural analysis
performed with biopsies obtained from experimental chimeric
vTK+ and vTK2 SCID/uPA mice (having RI.60%) demonstrate
aberrant mitochondrial features in hepatocytes from chimeric
vTK+ SCID/uPA mice that were administered GCV (not shown).
Discussion
The vTK/GCV strategy for cell-specific ablation in transgenic
animals is well documented[18]. This study demonstrates the
efficacy of this strategy in humanized SCID/uPA mouse liver for
the selective ablation of parenchymal MH to promote complete
humanization of SCID/uPA mouse liver. Hepatic sensitivity to
GCV was first established in vTK+FVB/N mice since the
development of hepatocellular disease, inherent to SCID/uPA
mice[8,9], was not a confounding factor. Hepatic vTK expres-
sion was found to be an integral component of GCV-induced
pathologic and biochemical alterations and caused death due to
liver dysfunction, similar to other vTK/GCV mouse models of
liver failure[19,20] and human liver disease caused by acute to
subacute toxin-mediated irreversible hepatocyte damage[21]. The
apparent sterility of male vTK+FVB/N mice has been described
previously for other vTK-transgenic mice and is likely due to the
expression of delta vTK in the testes shown to arise from an
Figure 7. Impact of vTK/GCV on hAAT production and human hepatocyte engraftement in chimeric SCID/uPA mice. A. Baseline blood
samples were obtained from experimental mice (Table 2) 1 h prior to the commencement of GCV dosing (t0) for hAAT analysis. Subsequent samples were
obtained from all chimeric mice for hAAT analysis once weekly for 2 weeks with the exception of v241 which had to be euthanized after 10 days of GCV dosing.
B. A correlation plot of final hAAT concentration vs. replacement index (RI) was constructed for those experimental mice (Table 2) that were severely impacted
by GCV(left)andthose thatremainedhealthydurin gth eco u rs eo fdo s i n gp eri o d( r ig h t ) .RIw asd et erminedasthe ratioof the area occupied by Alu-positive HH
relative to the entire area examined in the in situ hybridization sections expressed as percent. Data represent the mean RI +/2SEM of at least 3 separate lobes).
doi:10.1371/journal.pone.0009209.g007
SCID/uPA Mouse Liver Suicide
PLoS ONE | www.plosone.org 7 February 2010 | Volume 5 | Issue 2 | e9209Figure 8. Impact of vTK/GCV on the gross appearance of chimeric SCID/uPA liver. Chimeric livers from vTK2 SCID/uPA mice (Table 2)
exhibited multiple small red-colored foci (D, E, and F for mice V245, V244 and V238, respectively) that were clearly evident in liver from chimeric vTK+
SCID/uPA mice that did not receive GCV (A for mouse V250), but were diminished in chimeric livers from vTK+ SCID/uPA mice that received 25 and
100 mg/kg GCV doses (B and C, respectively). Occasionally, chimeric livers from chimeric mice also exhibited large 3-dimensional regenerative
nodules (RN).
doi:10.1371/journal.pone.0009209.g008
Figure 9. Histopathological changes induced by vTK/GCV in chimeric SCID/uPA mice. Engrafted human hepatocytes (HH, bordered by
dashed line) in paraffin embedded liver sections from experimental mice (Table 2) were identified by hybridization with fluoresceinated Alu probe
(top). Serial sections were analyzed by H& E staining (bottom). MH; mouse hepatoctyes. Original magnification 6100.
doi:10.1371/journal.pone.0009209.g009
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vTK minigene by SCID/uPA mice did not appear to impact
inherent ability of endogenous MH to develop into RN since by 3
months old, vTK+SCID/uPA mouse liver had architectural
features that typically mark the hepatocellular disease seen with
age-matched SCID/uPA mice[9,26]. Like their vTK+FVB/N
ancestors, biochemical and pathologic changes in the liver could
be regulated by GCV dose, and caused death due to liver
dysfunction. Most notable were the gross and pathologic changes
that occurred with RN. It is presumed that proliferating vTK
expressing cells are particularly more sensitive to GCV than
quiescent cells[18] since cells expressing vTK convert the nontoxic
prodrug GCV into GCV-triphosphate, which in turn leads to
chain termination and single-strand breakage upon incorporation
into DNA and ultimately cell death due to apoptosis[27]. GCV
sensitivity of RN is not surprising since they have been shown to
arise from the clonal expansion of MH that have an enhanced
proliferative capacity due to deletion of the uPA transgene[9]. The
vTK/GCV combination also killed normally non-proliferating
liver parenchymal cells of adult FVB/N mice and this observation
has been corroborated by several reports from experimental
animal models and from clinical trials suggesting that proliferation
is not a requisite for vTK/GCV-induced toxicity[28,29,30,31,32].
Therefore, it is likely that diseased PL surrounding RN in
vTK+SCID/uPA mouse liver also underwent further degenera-
tion from the cytotoxic effects of GCV.
Established human chimerism had only a minor therapeutic
advantage in the setting of GCV induced mouse liver failure; possibly
due to HH survival and continued expansion. However, despite
replacement of up to 87% of the endogenous parenchyma with HH,
GCV still induced liver failure and caused death. The known safe
limit for experimental liver resection in mice is 70% PH, versus 90%
PH, which was found to be lethal in all mice due to severe acute liver
failure[17]. This raises the question about whether a humanized liver
could replace all necessary mouse liver functions. Limited survival
beyond 3 months post-transplant has been described for chimeric
SCID/uPA mice with RI.50%[11] but this was due to severe insult
to host tissues induced by HH-secreted complement factor[11].
Survival of chimeric mice with RI.50% was achieved by admi-
nistering a drug that has anti-human complement factor activity; the
yield of healthy chimeric mice with RI.70% was 32% with the
maximum RI as high as 96%[11]. Although these authors also
achieved variable levels of human chimerism, the survival of healthy
mice with up to 96% human chimerism strongly suggests that the
capacity to satisfy metabolic demand is indeed securable by engrafted
HH. In this study, we demonstrate that the capacity of engrafted
vTK-negative HH to satisfy metabolic demands is compromised by
vTK/GCV induced damage within residual murine liver, even in
mice with up to 87% human chimerism. Our findings have been
corroborated by at least one other study in which wild-type MH
transplanted into Alb-vTK immune competent mice continued to
expand during GCV administration, but a consistent therapeutic
advantage in rescuing mice from GCV-induced liver disease could
not be demonstrated[19]. These observations are interesting with
respect to the known ‘bystander effect’ (BE) of vTK-expressing cells
incubated with GCV to induce apoptosis in neighboring vTK-
negative cells[33,34,35,36,37,38,39]. Generally speaking, the BE is
due to intercellular transfer of the activated pro-drug via gap
junctions thought to be restricted to dividing cells[38,40] and has
been shown to occur in vivo during the treatment of gliomas,
sarcomas, or carcinomas[41,42] and in clinical trials on the
assessment of vTK/GCV gene therapy for the treatment of brain
Figure 10. Induction of apoptosis by vTK/GCV in chimeric SCID/uPA mice. Engrafted human hepatocytes (bordered by dashed line) in
paraffin embedded liver sections from experimental mice (Table 2) were identified by hybridization with fluoresceinated Alu probe (left). Indirect
TUNEL analysis of DNA fragmentation was performed on serial sections (right). Original magnification 6100.
doi:10.1371/journal.pone.0009209.g010
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expressing cells has also been suggested as a potential mechanism[40]
but no functional evidence has been presented to date[18]. An
immunological component to the BE, involving CD4+ and CD8+
lymphocyte infiltration, has been described[46,47] and thought to
absent when experiments are conducted in immune-compromised
animals[48] such as SCID/uPA mice[8]. Many of the histopatho-
logical features that characterized vTK/GCV induced liver failure in
FVB/N mice and non-transplanted SCID/uPA mice were also
localized to the HH populations of chimeric liver. The paucity of
TUNEL-positive apoptotic MH and HH likely precludes their
involvement in vTK/GCV-induced hepatic failure in chimeric mice.
Given that hepatocytes harbor up to 2000 mitochondria per cell and
the oxidative phosphorylation capacity of animal tissues is regulated
primarily through replication and transcription of mitochondrial
DNA[49], any perturbation of mitochondrial integrity can lead to cell
death[49]. For SCID/uPA mice, normal hepatic capacity is restored
by the development of RN, be they from uPA-deficient MH or
HH[8,9]. Ultrastructural analysis revealed that vTK/GCV induced
severe mitochondrial aberrations, similar to those reported for liver
from rats that received combined administration of Ad.CMVtk and
GCV and in whom hepatotoxicity and mortality correlated with the
accumulation of phosphorylated GCV in the mitochondria,a drop in
mitochondrial membrane potential and a decrease in mitochondrial
DNA[50]. Apoptosis and aberrant mitochondria in bystander HH,
as far as we know, is the first indication that functional metabolic
coorperation between MH and HH exists in chimeric SCID/uPA
mouse liver. Strategies aimed at prevention of the BE will likely
facilitate the use of a vTK/GCV system for the development of a
mouse model with a completely humanized liver.
Materials and Methods
Ethics Statement: Animals
All mice were housed in a virus-free/antigen-free environment,
and cared for in accordance with Canadian Council on Animal
Figure 11. Ultrastructural changes after GCV treatment. A–B. Chimeric vTK+ SCID/uPA livers after GCV treatment (100 mg/kg) showing
swollen electron lucent mitochondria (A) with aberrant cristae and matrices (B). C–D. vTK+ SCID/uPA livers with no GCV showing normal cellular (C)
and mitochondrial (D) ultrastructure. E–F. vTK2 SCID/uPA livers showing normal cellular (E) and mitochondrial (F) ultrastructure (Uranyl acetate-lead
citrate, original magnification, A,C,E:61500; B,D,F:63600). These micrographs represent ultrastructural features that are present in 10 biopsies with a
minimum of 5 random fields examined per mouse.
doi:10.1371/journal.pone.0009209.g011
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approved by the University of Alberta Health Sciences Animal
Welfare Committee.
Cell Lines
Huh7 and 293T cells (American Type Culture Collection,
Rockville, MD) were maintained in Dulbecco’s Modified Eagle’s
Medium containing 10% heat-inactivated fetal calf serum, 100
Units of penicillin G sodium per ml, and 100 mg of streptomycin
sulfate per ml (DMEM-10).
Plasmids
The HSVtk coding region (vTK) was obtained by PCR
amplification from a plasmid containing the entire HSV-1 genome
(pTK173, a gift from Dr. Jim Smiley, University of Alberta) with
vTK/F (59-GCGCTCTAGATGGCTTCGTACCCCTGC-39) de-
rived from nt 1–18 (Italicized, beginning with the ATG start
codon) and vTK/R (59-CGCGTCTAGATC AGTTAGCCTCCCC-
CAT-39) derived from the antisense strand for nt 1111–1131
(Italicized) of the full-length vTK open reading frame (GenBank:
AF303108.1, 1131 bp). PCR reactions were performed in 25-ul
reaction mixtures using the following conditions: 90 s at 95uC,
then 28 cycles of 45 s at 95uC, 45 s at 58uC and 60 s at 72uC, and
finally 3 min at 72 C. Following digestion with Xba I, the vTK
amplicon (1131 bp) subcloned into the Xba I sites of pCIneo
(Promega), to generate pCI-vTK for expression of vTK in
mammalian cells, and pAlbHGF in place of HGF and down-
stream from a murine albumin promoter and enhancer sequence
(Alb p/e)[51] to generate pAlb-vTK, for targeted expression of
vTK to mouse liver. Sequence and orientation of cloned vTK was
confirmed by sequencing (University of Alberta, DNA Sequencing
Core Facility).
vTK/GCV Cytotoxicity in Huh7 Cells
Huh7 and 293T cells were transfected with pCI-vTK using
Lipofectamine 2000 (Invitrogen, Burlington, ON, Canada) and
G418 (Invitrogen, Burlington, ON, Canada)-resistant cellular
clones were selected according to the manufacturers’ directions.
Cellular expression of vTK protein was detected by immunoblot
analysis essentially as described[52] using a rabbit polyclonal anti-
vTK antibody (a gift from Dr. Jim Smiley, University of Alberta).
Cytotoxicity of GCV on cell cultures was determined using Cell
Proliferation Kit I (MTT) (Roche, Mississauga, ON) according to
the manufacturer’s instructions.
vTK Transgenic Mice
pAlb-vTK was digested with BstXI and HindIII to yield a
5134 bp minigene containing the murine Alb p/e with the
downstream vTK coding region which was microinjected into
fertilized oocytes prior to their transfer into the oviducts of
pseudopregnant FVB/N mice using standard procedures[53].
Transgenic (vTK+) and non-transgenic (vTK2) offspring were
identified by PCR of genomic DNA extracted from tail tissue
(DNeasy, Qiagen) using vTK/F and vTK/R primers and the
PCR conditions described above. All attempts to breed with male
vTK+ mice were unsuccessful. Female vTK+ FVB/N mice were
used to breed with male SCID/uPA (homozygous for the SCID
mutation and homozygous for the uPA transgene) mice. vTK
expression in the SCID(+,2)/uPA(+/2) (heterozygous for the
SCID mutation and hemizygous for the uPA transgene) offspring
was confirmed by PCR of tail DNA and the vTK+ female
offspring were used for interbreeding with SCID/uPA male mice.
Zygosity of SCID mutation and uPA transgene was determined
in offspring by established PCR based strategies. For SCID
genotyping, the forward primer was oIMR0803 (59-ggA AAA gAA
TTg gTA TCC AC-39) [54] and the reverse primer was
oIMR0804 (59-AgT TAT AAC AgC Tgg gTT ggC -39)[55].
PCR was performed in 50 ul reaction volumes using the following
conditions: 94uC for 1.5 min, then 35 cycles of 94uC for 30 s,
53uC for 30 s and 72uC 30 sec, and finally 72uC for 2 min. The
PCR amplified a 79 bp DNA fragment from both alleles which
was subjected to digestion for 2 h at 37 C with AluI. After AluI
digestion, products from the wild type allele are predicted to be 68
and 11 bp, and the products from the SCID allele are predicted to
be 38, 28, and 11 bp. Digestion products were visualized by
ethidium bromide staining following electrophoresis on a 4%
agarose gel. Genotyping for the uPA transgene was done using a
multiplex PCR procedure as described by Meuleman et al[56].
Only vTK+ and vTK2 SCID/uPA (homozygous for both the
SCID mutation and the uPA transgene) mice were used for testing
vTK/GCV inducible liver failure in chimeric (transplanted) and
non-transplanted mice.
Induction of Liver Damage
A range of GCV dosage concentrations (ranging from 0 to
100 mg GCV/kg body weight) was used to produce groups of
mice with variably severe liver disease essentially as described[19].
GCV was administered (i.p) every 48 h to mice at 12 weeks old.
All mice were monitored daily and were sacrificed if they showed
signs of metabolic crisis typified by weight loss, decreased activity,
ruffled fur, and hunched posture.
Transplantation of Mice
Ethical approval for human tissue was obtained from the
University of Alberta, Faculty of Medicine Research Ethics Board,
and informed consent was obtained from all human tissue donors.
Hepatocytes were collagenase isolated from phosphate-buffered
saline flushed normal human liver segments obtained from a
patient undergoing liver resection from liver cancer and Percoll
purified then injected into the inferior pole of the spleen of 7-day
old mice essentially as described[8,57]. Mice were monitored
weekly beginning at 8 weeks post transplant for engraftment
success using a serum-based hAAT ELISA[8,57].
Biochemical Analysis of Blood
Peripheral blood was sampled from the tail vein just 1 h prior to
the commencement of GCV dosing, then once weekly during the
course of GCV treatmuent. Serum samples underwent analysis for
human alpha-1 antitrypsin (hAAT) using methods we have
established previously[8,57] and for levels of aminotransferases
(ALT and AST) and creatinine (performed by the Central
Laboratory for Veterinarians, Ltd. Edmonton, AB).
Tissue Procedures
Tissues were removed, washed with cold PBS, frozen in liquid
nitrogen and stored at 280uC until processed. Protein homoge-
nates were prepared essentially as described[58] and analyzed for
vTK protein expression by immunoblot analysis (described above).
Total RNA was isolated from frozen tissue using TrizolH reagent
(Life Technologies, Inc., Burlington, ON, Canada) according to
the manufacturer’s instructions. First-strand cDNA synthesis from
2 mg of total RNA was performed using SuperScript
TM II reverse
transcriptase (Invitrogen, Burlington, ON, Canada) primed by
vTK/R. PCR was performed using vTK/F and vTK/R primers
as described above. For detection of a 59-truncated vTK RNA
(delta vTK), a different forward primer was used in the RT-PCR
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vTK/F) corresponding to nt 137–153 of the vTK coding region.
Freshly isolated liver samples were fixed in formalin, embedded
in paraffin, sectioned, and stained with hematoxylin and eosin
(H&E), periodic acid-Schiff’s (PAS) with or without diastase.
Apoptotic cells were detected in situ by the indirect TUNEL
method using the ApopTagH Peroxidase In Situ Apoptosis
Detection Kit (Chemicon, S7100, Temecula, CA) according to
the manufacturer’s instructions. Engrafted HH in paraffin
embedded liver sections were identified using the Super Sensitive
ISH Detection System (Biogenex, San Ramon, CA) with
fluoresceinated Alu probe (cat # HK844-2K, Biogenex, San
Ramon, CA) according to the manufacturer’s instructions.
Electron Microscopy
Tissues were freshly isolated from vTK+ and vTK-SCID/uPA
mouse liver by microdissection (10 random biopsies per mouse
liver) and processed for transmission electron microscopy (TEM).
Tissue for transmission electron microscopy (TEM) was placed
rapidly in 1% glutaraldehyde, fixed for at least 1 h at room
temperature, and post-fixed in osmium tetroxide, and then
processed into plastic. The ultramicrotome was then used to
prepare thin sections, which were collected on a copper grid and
stained with lead citrate and uranyl acetate [59]. A minimum of 5
random fields per biopsy was examined by TEM.
Statistics
Comparisons between variables were tested by Student t test of
means, the paired Student t test or Mann–Whitney U test, as
appropriate. P,0.05 was considered statistically significant.
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